The research project will make use of new technologies for decoding or "sequencing" DNA, which have made it possible for researchers to study DNA more rapidly and at a lower cost than ever before. In cancer, the scientists will create catalogs of the genetic abnormalities (called "mutations") that occur across different cancer types. Such knowledge aims to reveal key genetic weaknesses that can be exploited by new cancer therapies and to identify which patients are most likely to respond to specific cancer drugs.
In type 2 diabetes, the researchers will also assemble systematic descriptions of the genetic factors underlying the disease, with a special focus on Latin American populations. Diabetes is among the most common inherited diseases in Latin America, yet a deep knowledge of the genetic risk factors in the region's populations is lacking. A profound understanding of these factors is needed in order to foster prevention, treatment, and control.
During the three years of the project, major findings will be publicly announced. In order to guarantee that the project benefits science and the population in general, the main recipient of its findings will be the National Institute for Genomic Medicine.
To supervise the scientific progress of the project a Scientific Advisory Board has been established. It is composed of renowned scientists from around the world with vast experience in the fields of cancer, diabetes, and genomic science.
|Contact: Nicole Davis|
Broad Institute of MIT and Harvard